Pal A, Raja S
Arch Razi Inst. 2024; 79(2):287-302.
PMID: 39463725
PMC: 11512181.
DOI: 10.32592/ARI.2024.79.2.287.
Maehara Y, Oki E, Ota M, Harimoto N, Ando K, Nakanishi R
Int J Clin Oncol. 2023; 28(5):613-624.
PMID: 36961615
DOI: 10.1007/s10147-023-02326-w.
Sakai S, Kobuchi S, Ito Y, Sakaeda T
Eur J Drug Metab Pharmacokinet. 2021; 46(2):301-315.
PMID: 33606175
DOI: 10.1007/s13318-021-00674-4.
Shida M, Yasuda M, Fujita M, Miyazawa M, Kajiwara H, Hirasawa T
Oncol Lett. 2016; 12(5):3215-3223.
PMID: 27899985
PMC: 5103922.
DOI: 10.3892/ol.2016.5082.
Bayoglu I, Yildiz I, Varol U, Cokmert S, Alacacioglu A, Kucukzeybek Y
Contemp Oncol (Pozn). 2016; 19(5):385-90.
PMID: 26793023
PMC: 4709396.
DOI: 10.5114/wo.2015.53374.
High-dose oral tegafur-uracil maintenance therapy in patients with uterine cervical cancer.
Sakaguchi I, Motohara T, Saito F, Takaishi K, Fukumatsu Y, Tohya T
J Gynecol Oncol. 2015; 26(3):193-200.
PMID: 25686399
PMC: 4510335.
DOI: 10.3802/jgo.2015.26.3.193.
Effect of Uridine on the Metabolism of 5-Fluorouracil in the CD8F 1 Murine Mammary Carcinoma System.
Sawyer R, Stolfi R, Spiegelman S, Martin D
Pharm Res. 2013; 1(2):69-75.
PMID: 24277215
DOI: 10.1023/A:1016351330832.
Effects of 5-Fluorouracil prodrugs on the central nervous system in mice and rats.
Toide K, Unemi N, Segawa T
Pharm Res. 2013; 2(2):83-6.
PMID: 24272616
DOI: 10.1023/A:1016394829072.
Clinical identification of colorectal cancer patients benefiting from adjuvant uracil-tegafur (UFT): a randomized controlled trial.
Fujii M, Takayama T, Kochi M
J Cancer Res Clin Oncol. 2008; 134(12):1319-23.
PMID: 18512074
DOI: 10.1007/s00432-008-0417-z.
Proteomic analysis of stage I primary lung adenocarcinoma aimed at individualisation of postoperative therapy.
Maeda J, Hirano T, Ogiwara A, Akimoto S, Kawakami T, Fukui Y
Br J Cancer. 2008; 98(3):596-603.
PMID: 18212748
PMC: 2243141.
DOI: 10.1038/sj.bjc.6604197.
UFT (tegafur and uracil) as postoperative adjuvant chemotherapy for solid tumors (carcinoma of the lung, stomach, colon/rectum, and breast): clinical evidence, mechanism of action, and future direction.
Tanaka F
Surg Today. 2007; 37(11):923-43.
PMID: 17952521
DOI: 10.1007/s00595-007-3578-5.
Gene expression analysis using human cancer xenografts to identify novel predictive marker genes for the efficacy of 5-fluorouracil-based drugs.
Ooyama A, Takechi T, Toda E, Nagase H, Okayama Y, Kitazato K
Cancer Sci. 2006; 97(6):510-22.
PMID: 16734730
PMC: 11158588.
DOI: 10.1111/j.1349-7006.2006.00204.x.
Angiogenesis and the efficacy of postoperative administration of UFT in pathologic stage I non-small cell lung cancer.
Tanaka F, Yanagihara K, Otake Y, Miyahara R, Wada H
Cancer Sci. 2004; 95(4):371-6.
PMID: 15072598
PMC: 11158538.
DOI: 10.1111/j.1349-7006.2004.tb03218.x.
Plasma concentrations of 5-fluorouracil and F-beta-alanine following oral administration of S-1, a dihydropyrimidine dehydrogenase inhibitory fluoropyrimidine, as compared with protracted venous infusion of 5-fluorouracil.
Yamada Y, Hamaguchi T, Goto M, Muro K, Matsumura Y, Shimada Y
Br J Cancer. 2003; 89(5):816-20.
PMID: 12942110
PMC: 2394492.
DOI: 10.1038/sj.bjc.6601224.
Prediction of sensitivity to fluoropyrimidines by metabolic and target enzyme activities in gastric cancer.
Terashima M, Fujiwara H, Takagane A, Abe K, Irinoda T, Nakaya T
Gastric Cancer. 2003; 6 Suppl 1:71-81.
PMID: 12775024
DOI: 10.1007/s10120-003-0221-z.
Relationships between body composition parameters and fluorouracil pharmacokinetics.
Gusella M, Toso S, Ferrazzi E, Ferrari M, Padrini R
Br J Clin Pharmacol. 2002; 54(2):131-9.
PMID: 12207632
PMC: 1874401.
DOI: 10.1046/j.1365-2125.2002.01598.x.
Oral tegafur/uracil.
Wellington K, Goa K
Drugs Aging. 2002; 18(12):935-48; discussion 949-50.
PMID: 11888348
DOI: 10.2165/00002512-200118120-00005.
Phase II study of S-1, a novel oral fluorouracil, in advanced non-small-cell lung cancer.
Kawahara M, Furuse K, Segawa Y, Yoshimori K, Matsui K, Kudoh S
Br J Cancer. 2001; 85(7):939-43.
PMID: 11592762
PMC: 2375091.
DOI: 10.1054/bjoc.2001.2031.
Apoptosis and p53 status predict the efficacy of postoperative administration of UFT in non-small cell lung cancer.
Tanaka F, Otake Y, Yanagihara K, Yamada T, Miyahara R, Kawano Y
Br J Cancer. 2001; 84(2):263-9.
PMID: 11161386
PMC: 2363717.
DOI: 10.1054/bjoc.2000.1579.
Phase II study of S-1, a novel oral fluorophyrimidine derivative, in patients with metastatic colorectal carcinoma. S-1 Cooperative Colorectal Carcinoma Study Group.
Ohtsu A, Baba H, Sakata Y, Mitachi Y, Horikoshi N, Sugimachi K
Br J Cancer. 2000; 83(2):141-5.
PMID: 10901361
PMC: 2363492.
DOI: 10.1054/bjoc.2000.1236.